Latest US KDOQI Anaemia Guidelines update - What are the implications for Europe?

Nephrology Dialysis Transplantation

Volumn 22, Issue 10, 2007, Pages 2738-2742

  Macdougall, Iain C ^a   Eckardt, Kai Uwe ^b   Locatelli, Francesco ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c A MANZONI HOSPITAL   (Italy)

Author keywords

Anaemia; CHOIR; Clinical guidelines; CREATE; EBPG; KDIGO; KDOQI; TREAT

Indexed keywords

ANTIARRHYTHMIC AGENT; ATORVASTATIN; ENCAINIDE; ERYTHROPOIETIN; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DRESSLER SYNDROME; ESTROGEN THERAPY; EUROPE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEMODIALYSIS; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HYPOTHESIS; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICARE; MORTALITY; NOTE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE; UNITED STATES;

ANEMIA; CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; KIDNEY DISEASES; NEPHROLOGY; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 36048973287     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm562     Document Type: Note

References (23)

1. Manson JE, Hsia J, Johnson KC et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-534
2. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-788
3. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
4. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
5. Besarab A, Bolton WK, Brown JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
6. Macdougall IC, Ritz E. The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998; 13: 3030-3033
7. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
8. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 335: 2071-2084
9. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 335: 2085-2098
10. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309-312
11. Singh AK, Szczech L, Tang KL et al. Anaemia of CKD - the CHOIR study revisited. Nephrol Dial Transplant 2007; 22: 1806-1810
12. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a metaanalysis. Lancet 2007; 369: 381-388
13. Strippoli GFM, Tognoni G, Navaneethan SD et al. Haemoglobin targets: we were wrong, time to move on. Lancet 2007; 369: 346-350
14. Mix TCH, Brenner RM, Cooper ME et al. Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005; 149: 408-413
15. Pfeffer M. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 2007; 356: 9
16. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47 [Suppl. 3]: S1-S145
17. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. Am J Kidney Dis 2007; 50: 471-530
18. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: ii1-ii47
19. Pollock C, McMahon L. Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Biochemical and haematological targets guidelines. Haemoglobin. Nephrology 2005; 10 [Suppl 4]: S108-S115
20. Barrett BJ, Fenton SS, Ferguson B et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 1999; 10 [Suppl 13]: S292-S296
21. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058-2065
22. Vanbelleghem H, Vanholder R, Levin NW et al. The Kidney Disease: Improving Global Outcomes website: comparison of guidelines as a tool for harmonization. Kidney Int 2007; 71: 1054-1061
23. Uhlig K, Balk EM, Lau J, Levey AS. Clinical practice guidelines in nephrology-for worse or for better. Nephrol Dial Transplant 2006; 21: 1145-1153